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Abstract
Background: Expenditure on medications for highly prevalent chronic conditions such as diabetes mellitus (DM)
can result in financial impoverishment. People in developing countries and in low socioeconomic status groups are
particularly vulnerable. China and India currently hold the world’s two largest DM populations. Both countries are
ageing and undergoing rapid economic development, urbanisation and social change. This paper assesses the
determinants of DM medication use and catastrophic expenditure on medications in older adults with DM in China
and India.
Methods: Using national standardised data collected from adults aged 50 years and above with DM (self-reported)
in China (N = 773) and India (N = 463), multivariable logistic regression describes: 1) association between respondents’
socio-demographic and health behavioural characteristics and the dependent variable, DM medication use, and 2)
association between DM medication use (independent variable) and household catastrophic expenditure on
medications (dependent variable) (China: N = 630; India: N = 439). The data source is the World Health Organization
(WHO) Study on global AGEing and adult health (SAGE) Wave 1 (2007–2010).
Results: Prevalence of DM medication use was 87% in China and 71% in India. Multivariable analysis indicates that
people reporting lifestyle modification were more likely to use DM medications in China (OR = 6.22) and India (OR = 8.45).
Women were more likely to use DM medications in China (OR = 1.56). Respondents in poorer wealth quintiles in China
were more likely to use DM medications whereas the reverse was true in India. Almost 17% of people with DM in China
experienced catastrophic healthcare expenditure on medications compared with 7% in India. Diabetes medication use
was not a statistically significant predictor of catastrophic healthcare expenditure on medications in either country,
although the odds were 33% higher among DM medications users in China (OR = 1.33).
Conclusions: The country comparison reflects major public policy differences underpinned by divergent political and
ideological frameworks. The DM epidemic poses huge public health challenges for China and India. Ensuring equitable
and affordable access to medications for DM is fundamental for healthy ageing cohorts, and is consistent with the global
agenda for universal healthcare coverage.
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Background
In all parts of the world people are living longer, overall
health has improved, and average income levels are rising.
Yet despite major social and economic advancements,
additional years of life are not always lived in good health.
Economic development is associated with a number of so-
cial and demographic changes, covering urbanisation and
the adoption of unhealthy lifestyle behaviours, including
lack of physical exercise, tobacco use and excess alcohol
consumption. These activities can lead to metabolic and
physiological changes, such as high blood pressure,
obesity, raised blood glucose and elevated cholesterol -
all of which are risk factors for non-communicable diseases
(NCDs). In recent decades the main causes of death and
disability have shifted away from infectious diseases with
NCDs now responsible for about 70% of premature
mortality [1, 2]. At the Political Declaration on the Pre-
vention and Control of NCDs in 2011, world leaders
targeted four major NCD global priorities - cardiovascular
disease, cancer, chronic respiratory diseases and diabetes
mellitus (DM) [3].
China and India are the world’s two most populous
countries with populations of 1.4 and 1.3 billion respect-
ively [4]. More than 30% of adults aged over 50 now live
in either country with this proportion expected to
approach 40% by 2050. China and India hold prominent
positions at global and regional levels and both countries
are experiencing economic growth, demographic ageing,
urbanisation and changes in population health. These
policy elements alone warrant comparisons to better
understand and project global disease burdens. Yet of
particular interest are the differing trajectories of eco-
nomic growth and epidemiological transition occurring
in the two population superpowers [5–11].
China’s rapid economic growth has led to extraordinary
increases in real living standards, improved access to
government-funded healthcare and a decline in poverty
[12]. India’s economic growth has been much slower,
poverty rates remain high and the majority of the popu-
lation do not have access to affordable healthcare [13].
Both countries are experiencing altered morbidity bur-
dens due to increased life expectancies. China has made
good progress with regard to successful infectious dis-
ease control, but now faces a rising epidemic of NCDs.
India is experiencing a double burden of both commu-
nicable and NCDs [5, 6, 9]. This study compares factors
associated with DM, medication use and catastrophic
healthcare expenditure in China and India.
Diabetes mellitus (diabetes) increases the risk of serious
morbidity and premature death from cardiovascular com-
plications [14]. The condition occurs either when the pan-
creas does not produce enough insulin (type 1) or when
the body cannot use the insulin it produces effectively,
resulting in elevated plasma glucose levels (type 2) [15].
Over 90% of people with DM have type 2. This can be
delayed or prevented by behaviour change, such as ceasing
tobacco smoking, adhering to a healthy diet, and engaging
in physical activity. Medications for DM are on the World
Health Organization (WHO) list of essential medicines.
People with type 1 DM cannot survive without injections
of insulin. A number of medications are available for
people with type 2 DM. People with all types of DM can
also require medications for blood pressure and choles-
terol control [16].
Diabetes has been described as one of the medical
emergencies of the 21st century [16]. In 2015, the Inter-
national Diabetes Federation (IDF) estimated that world-
wide about 415 million adults aged 20–79 years (about
8.8%) had DM and that the condition accounted for 12%
of global healthcare expenditure. The IDF predicts that,
if current trends continue, by 2040 one in ten adults will
have DM [16].
Current estimates are that about 75% of people with
DM live in low- and middle-income countries (LMICs)
[16]. In 2015 China had the world’s largest population of
adults (aged 20–79 years) with DM at 109.6 million.
India ranked second with 69.2 million adult cases [16].
The age-adjusted DM prevalence in 20–79 year olds at
9.8% in China and 9.3% in India. Diabetes poses enor-
mous public health challenges for both countries [16].
Between 2015 and 2040, China is expected to experience
a 37.5% increase in the numbers of adults (20–79 years)
with DM (to 150.7 million). On current projections, the
absolute numbers of adults with DM in 2040 will be
larger in China than in India (150.7 million compared
with 123.5 million). However India is expected to
experience a 117.8% increase in the numbers of adults
with DM between 2015 and 2040 (from 69.2 million to
123.5 million) [16].
Diabetes impacts disproportionately on those who are
older and socially and economically vulnerable [16–19].
In 2015, the United Nations General Assembly adopted
the 2030 Agenda for Sustainable Development [20, 21].
Countries agreed to: take action to reduce premature
mortality from DM and other NCDs by one-third;
achieve universal healthcare coverage (UHC), and pro-
vide access to affordable essential medicines. See http://
www.idf.org/action-on-diabetes/sdgs.
One of the impediments to achieving UHC is reliance
on out-of-pocket (OOP) payments. These are fees paid
by the patient to the provider at the time of the service
[22] and they can include payments made for consulta-
tions, procedures and medicines [23, 24]. It is estimated
OOP payments comprise an overwhelming majority of
household medical expenditure in developing countries
and that about one third of people in developing coun-
tries are unable to afford essential medicines on a regu-
lar basis [25, 26].
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According to the World Bank, between 2011 and
2015, OOP expenditure as a percentage of private
expenditure on health, was 72.3% in China and 89.2% in
India [27]. Catastrophic healthcare expenditure refers to
situations where households make OOP payments for
healthcare above a reasonable proportion of their income
[28] one of the consequences of which is decreased
spending on food and other essentials [29]. In a study
which described the magnitude and distribution of
OOP payments and catastrophic expenditures in Asia,
China and India were identified as relying heavily on
OOP payments and having a high incidence of cata-
strophic payments for healthcare [26]. Catastrophic
healthcare expenditure was estimated at 13.0% in China
in 2008 [30]. Research in India suggests that in addition
to having DM, people living in rural areas [31] and having
lower incomes, incur higher OOP payments [32].
The authors of a literature review of NCD costs in
LMICs concluded that NCDs impose a disproportionate
financial burden on poorer households. Expenditure on
medications and treatments for DM comprise a major
source of household expenditure on healthcare [33]. An-
other review on this topic showed that in LMICs, 6–11%
of the total population would be impoverished if they
had to purchase even low-priced generic medications for
DM [34]. A study which analysed the findings of a
national survey conducted in China in 2008 found that
healthcare costs were higher for people with DM com-
pared with people with normal glucose tolerance [35].
Given the global debates about UHC and healthcare
financing, and the increasing prevalence of NCDs
alongside ageing populations, there is now, more than
ever, a need to develop and implement social protection
policies as a way of improving financial risk protection
for healthcare. This is particularly important for LMICs,
where the financial costs are largely borne by individuals
and households [26, 33, 36]. Some research has looked
into the financial impact of NCDs in high-income coun-
tries and the evidence base for LMICs is slowly amassing
[33, 37]. An analysis of data from in 35 LMICs in the
World Health Surveys (2002–2003) showed that, re-
gardless of insurance coverage, diabetic individuals
(aged > =18 years) were more likely to experience cata-
strophic medical spending [29].
Globally there is major public health concern about the
health and economic consequences of DM with attention
directed to two countries in the Asia-Pacific region which
are home to more than 30% of the world’s population
[4, 16, 21, 38]. This study unpacks factors associated
with medication use and catastrophic expenditure on
medications among adults with self-reported DM in
China and India. The China India comparison will pro-
vide insights into how health system characteristics
might differently impact on catastrophic healthcare
expenditure in households in which there are people
with DM.
The aims are to assess the determinants of medication
use and catastrophic expenditure on medications in
adults aged 50 years and above who self-reported DM in
national surveys conducted in China and in India. The
research questions are as follows. Among older adults in
China and India who report having DM, what factors
are associated with medication use? Are households in
which there are people with DM more likely to incur
catastrophic expenditure on medicines? To our know-
ledge, this is the first study of its type. In addition to
informing global policies and interventions for people
with DM in China and India, the findings draw attention




The data source for this study is the WHO Study on global
AGEing and adult health (SAGE) Wave 1 (2007–2010).
WHO-SAGE is a longitudinal study of health and ageing
in six LMICs - China, Ghana, India, Mexico, Russia and
South Africa. This study covers China and India only. The
cohorts comprise nationally representative samples of
“older adults” aged 50 years and above. This age cut-point
is consistent with the WHO definition of younger and
older adults in LMICs [39]. Data were collected using
structured household and individual questionnaires
administered in face-to-face interviews conducted in
local languages. The individual questionnaire includes
information on sociodemographic factors, health states
and behaviours and medication use. The household
questionnaire includes information on dwelling charac-
teristics, asset ownership, income and expenditure.
WHO-SAGE employed a stratified random sampling
strategy in all countries with households as the final
sampling units. The strata ensure representation of a
range of living conditions and urban and rural localities
in each country. The probability proportional to size
sampling method was used to select primary sampling
units (PSUs) within the strata - towns in China and vil-
lages in India - and households were selected randomly
within PSUs Household-level analysis weights and
person-level analysis weights were calculated for each
country and post-stratification weights are used to adjust
for age and sex distributions and non-response [40].
Data from WHO-SAGE are in the public domain and
details are reported elsewhere [39].
Study variables derived from the individual questionnaire
The study population was conditioned on confirmatory
responses to the question: Have you ever been diagnosed
with diabetes (high blood sugar)? (Not including diabetes
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associated with a pregnancy) in the individual question-
naire. Those who answered “yes” were categorised ac-
cording to whether they had been taking insulin or other
blood sugar lowering medications either 1) in the last
two weeks or 2) in the last twelve months. The binary
medication variable enables a two-group comparison be-
tween past-year DM medications users and others who
reported non-use of DM medications.
Socio-demographic variables are sex, age, residence,
marital status, educational status and wealth status. Sex
is male or female. The age categories are 50–59 years
versus 60–69 years versus 70–79 years versus 80+ years.
Residence is urban or rural. Marital status is never mar-
ried versus married/cohabiting, versus divorced or
widowed. Educational status is primary school or less,
versus secondary or high school, versus university or
higher.
Health behaviour variables are body mass index (BMI),
nutrition and physical activity. The BMI variable is derived
from physical measurements of weight in kilograms (kgs)
and height in metres (ms). The WHO guidelines on
appropriate BMI for Asian populations [41] are used to
derive the categories high BMI (> = 30 kg/m2) versus
low BMI (<30 kg/m2). The nutrition variable is derived
from reported daily intake of fruit and vegetables (> = 5
servings daily) versus insufficient intake of fruit and
vegetables [42, 43]. Physical activity is measured using
the Global Physical Activity Questionnaire [44, 45]. The
classification is low versus moderate versus high. The
lifestyle modification variable classifies “yes” or “no”
responses to the question: have you been following a
special diet, exercise regime or weight control program
for diabetes during the last 2 weeks? (As recommended
by health professional).
Study variables derived from the household
questionnaire
Wealth status is derived from information on dwelling
characteristics (e.g., cooking oil, floor and roof types),
ownership of durable goods (e.g., radio, car) and access
to basic services (e.g., electricity, clean water and sanita-
tion). Principal Components Analysis was used to generate
weights from which raw continuous scores were derived.
These scores were transformed into wealth quintiles which
are included in the individual questionnaire dataset.
Here quintile 1 includes individuals in the wealthiest or
richest households and quintile 5 includes individuals
in the poorest or least wealthiest households [46, 47].
The quintiles were set in the original data and therefore
the use of survey sampling weights modify this distribu-
tion. Owing to small cell sizes the poorest two wealth
quintiles were merged for the analysis of catastrophic
expenditure.
Catastrophic healthcare expenditure on medications is
a binary variable estimated by summing mandatory and
voluntary expenditures reported for medications. There is
discussion in the literature about appropriate cut points
for catastrophic healthcare expenditure [28]. Using evi-
dence from other studies of healthcare expenditure on
medications in LMICs, catastrophic expenditure is
defined as > 40% of reported household income spent
on medications [33].
The household financial status variable was derived
from responses to the question: Would you say your
household's financial situation is (either): very good;
good; moderate; bad, or very bad? Due to small numbers
in the cells the “very good” and “good” categories were
combined as were the “very bad” and “bad” categories.
Information in the household questionnaire is also
used to derive a variable that describes the educational
status of the household head as: no schooling versus pri-
mary school or less versus secondary/high school versus
university or higher.
Data preparation and study sample
Figure 1 shows the derivation of the study samples in
China and India. The available study populations of
SAGE Wave 1 respondents was 27,248 of whom 15,050
were in China and 12,198 in India. Only respondents
aged 50 years and above who completed the SAGE sur-
veys were included. Eligibility for the study sample also
required that respondents: 1) reported having been diag-
nosed with DM or high blood sugar, not including DM
associated with a pregnancy, and 2) had non-missing re-
sponses to the questions asked about DM medications
use, either in the past year or past two weeks, and on
any other study variables in the individual questionnaire.
After satisfying the above criteria, two study samples
from China (N = 773) and India (N = 463), were used for
the analysis of DM medication use. A many-to-one
merge was performed between the individual and house-
hold questionnaire datasets. Records with missing data
on household study variables were excluded, giving study
samples of 630 in China and 439 in India for the analysis
of household catastrophic healthcare expenditure on
medications.
Ethics statement
The SAGE study was approved by the Ethics Review
Committee, World Health Organization, Geneva,
Switzerland; the Ethics Committee, Shanghai Municipal
Centre for Disease Control and Prevention, Shanghai,
China, and the Institutional Review Board, International
Institute of Population Sciences, Mumbai, India. Approval
covered all procedures undertaken as part of the study. All
participants gave written informed consent.
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Statistical analysis
Chi-squared tests of statistical significance compare
socio-demographic and health behavioural characteris-
tics by DM medication use in China and India. Multi-
variable logistic regression describes association between
individual socio-demographic and health behavioural
characteristics and the dependent variable, DM medica-
tion use. The selection of independent variables was in-
formed by the literature on health seeking behaviour and
health service utilization in developing countries [48, 49].
Chi-squared tests of significance compare household
characteristics by catastrophic household healthcare ex-
penditure on medications. Multivariable logistic regres-
sion describes association between DM medication use
(independent variable) and catastrophic household health-
care expenditure on medications (dependent variable)
while adjusting for possible confounding by household
socioeconomic characteristics (residence, wealth quin-
tile, financial status, and the educational status of the
household head).
The regression models were tested for multicollinearity
using the variance inflation factor (VIF) statistic. All
analyses included survey sampling weights. The statistical
software used here was STATA version 13 (Stata Corp,
Lakeway Dr, College Station, TX 77845, USA).
Results
Table 1 compares socio-demographic and health be-
havioural characteristics by DM medication use in
China and India. Almost 90% of people with DM in
China were using DM medications compared with 71%
in India. Significantly higher proportions of medication
users reported lifestyle modification in China (81.2%.
versus 40.6%¸ p < 0.01) and India (69.9% versus 33.1%,
p < 0.05). In China a higher proportion of medication
users were females (59.9%) than non-users (50.6%). In
India these proportions of users versus non-users were
39.1 and 32.6% respectively. There were statistically
significant differences in household wealth by DM
medication use only in India. In India, over 35% of
non-DM medication users were in the poorest two
household wealth quintiles compared with about 11%
of non-users (p < 0.05). In China, there were significant
differences by BMI in DM medications use (p < 0.05).
Fig. 1 Derivation of Study Sample
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Table 1 Socio-demographic and health behavioural characteristics by diabetes medication use, adults aged 50+ years, China and
India, SAGE Wave 1, 2007–2010
China India
No meds Meds Total No meds (N = 134) Meds (N = 329) Total
N (a %) N (a %) N (a %) N (a %) N (a %) N (a %)
Overall 101 (13.1) 672 (86.9) 773 (100) 134 (28.9) 329 (71.1) 463 (100)
Lifestyle modification
No 54 (59.4)*** 138 (18.8) 192 (24.7) 104 (66.9)** 97 (30.1) 201 (39.9)
Yes 47 (40.6) 534 (81.2) 581 (75.3) 30 (33.1) 232 (69.9) 262 (60.1)
Sex
Male 50 (49.4)* 275 (40.1) 325 (41.4) 73 (67.4) 180 (60.9) 253 (62.7)
Female 51 (50.6) 397 (59.9) 448 (58.6) 61 (32.6) 149 (39.1) 210 (37.3)
Age groups (years)
50–59 33 (36.1) 185 (28.2) 218 (29.4) 53 (57.3) 135 (50.8) 188 (52.5)
60–69 33 (34.7) 235 (38.7) 268 (38.1) 48 (26.7) 117 (28.6) 165 (28.1)
70–79 30 (26.2) 204 (27.4) 234 (27.2) 24 (11.4) 65 (18.1) 89 (16.3)
80+ 5 (3.1) 48 (5.8) 53 (5.4) 9 (4.6) 12 (2.5) 21 (3.1)
Residence
Urban 71 (67.0) 522 (75.0) 593 (73.8) 64 (44.7) 172 (48.9) 236 (47.8)
Rural 30 (33.0) 150 (25.0) 180 (26.2) 70 (55.3) 157 (51.1) 227 (52.2)
Marital status
Never married 1 (2.0) 2 (0.3) 3 (0.6) 1 (0.1) 2 (0.03) 3 (0.06)
Married/cohabitating 87 (87.5) 549 (83.5) 636 (84.1) 91 (82.8) 257 (84.3) 348 (83.9)
Divorced/widowed 13 (10.5) 121 (16.2) 134 (15.3) 42 (17.0) 70 (15.7) 112 (16.1)
Educational attainment
University or higher 9 (5.9) 46 (6.7) 55 (6.6) 12 (9.6) 48 (15.6) 60 (14.0)
Secondary/High School 39 (38.1) 273 (40.2) 312 (39.9) 33 (38.8) 102 (33.3) 135 (34.8)
Primary school or less 53 (56.0) 353 (53.1) 406 (53.5) 89 (51.7) 179 (51.1) 268 (51.3)
Household wealth
1 (Richest) 30 (28.8) 162 (28.1) 192 (28.2) 53 (37.1)** 147 (48.3) 200 (45.3)
2 27 (28.5) 181 (27.0) 208 (27.2) 31 (17.3) 99 (28.6) 130 (25.6)
3 21 (24.0) 152 (22.0) 173 (22.3) 21 (10.1) 47 (12.0) 68 (11.5)
4 15 (11.6) 108 (15.6) 123(15.0) 18 (29.2) 22 (7.2) 40 (13.1)
5 (Poorest) 8 (7.0) 69 (7.4) 77 (7.3) 11 (6.4) 14 (3.9) 25 (4.5)
BMI
Low 62 (59.3)** 338 (47.6) 400 (49.3) 105 (67.9) 222 (68.5) 327 (68.3)
High 39 (40.7) 334 (52.4) 373 (50.7) 29 (32.1) 107 (31.5) 136 (31.7)
Nutrition
Adequate 75 (82.2) 510 (79.2) 585 (79.7) 9 (4.4) 31 (9.3) 40 (8.0)
Inadequate 26 (17.8) 162 (20.8) 188 (20.4) 125 (95.6) 298 (90.7) 423 (92.0)
Physical activity
High 26 (28.0)** 191 (32.6) 217 (31.9) 62 (63.1) 127 (44.9) 189 (49.8)
Moderate 28 (23.1) 232 (33.6) 260 (32.1) 31 (17.0) 99 (29.4) 130 (26.1)
Low 47 (48.9) 249 (33.8) 296 (36.0) 41 (19.9) 103 (25.7) 144 (24.1)
Pearson χ2 tests undertaken for country comparisons. *p-value < 0.10; **p-value < 0.05; ***p-value < 0.01
asurvey sampling weights used to give percentage estimates. Percentages may not sum due to rounding
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Over 52% of users were in the high BMI group com-
pared with 40.7% of non-users. A significantly (p < 0.05)
higher proportion of DM medication users compared with
non-users reported high physical activity in China (32.6%
versus 28.0%).
Table 2 presents the multivariable logistic regression
of socio-demographic and health behavioural characteris-
tics by DM medication use in China and India. People
who reported lifestyle modification were six times more
likely to use DM medications in China (OR 6.22; 95%
CI:3.80–10.20) and eight times more likely to use DM
medications in India (OR 8.45; 95% CI:3.97–18.0). The
odds of females using DM medications in China were
almost 60% higher than for males (OR 1.56; 95%
CI:0.99–2.47) although the result was significant only at
p < 0.10. People in the poorer wealth quintiles in China
were more likely to use DM medications whereas the
reverse was true in India. For example, people in the
second poorest wealth quintile in China were twice as
likely to use DM medications (OR 2.13; 95% CI:0.86–5.26)
although the result was not statistically significant. How-
ever in India the odds of people in the second poorest
wealth quintile using DM medications were statically
significant (p < 0.05) and 86% lower than the odds in
the richest quintile (OR 0.14; 95% CI:0.03–0.69).
Table 3 compares household characteristics by cata-
strophic healthcare expenditure and shows that 16.8% of
people with DM in China experienced catastrophic
healthcare expenditure compared with 6.6% in India. In
China significantly (p < 0.01) higher proportions house-
holds with catastrophic healthcare expenditure were in
rural areas (49.3%) compared with people in households
without catastrophic healthcare expenditure (29.1%).
The data show an education gradient for catastrophic
healthcare expenditure in China; over 67% of households
that experienced catastrophic healthcare expenditure
had household heads with primary school or less educa-
tion compared with about 47% in households without
catastrophic healthcare expenditure.
In the multivariable logistic (Table 4) DM medication
use was not a statistically significant predictor of cata-
strophic healthcare expenditure in either country,
although in China higher (n = 630) the estimated odds of
catastrophic healthcare expenditure were 30% higher for
DM medication users (OR 1.32; 95% CI:0.50–3.51).
Compared with those in the highest (richest) wealth
quintile in China, people in the two poorest quintiles
were three and a half times more likely to be in house-
holds with catastrophic healthcare expenditure (OR 3.49;
95% CI:1.37–8.87). In India (n = 439) household financial
status was significantly associated with catastrophic
healthcare expenditure. People who reported very bad
or bad compared with very good or good financial sta-
tus, were less likely to be in households incurring
catastrophic healthcare expenditure (OR 0.14; 95%
CI:0.03–0.82).
Discussion
This study of adults aged 50 years and above in China
and India with self-reported DM improves understanding
of factors associated with DM medication use and cata-
strophic expenditure on medications and highlights diver-
gent public health policies in these two rapidly developing
populous countries. In China, healthcare costs are borne
by the large government controlled public sector which is
now responsible for the roll-out of UHC [50]. In India
healthcare is financed by out-of-pocket (OOP) payments
and private healthcare insurance with access to health-
care favouring higher socioeconomic groups [10].
Questions such as:“are there health system characteris-
tics that make people more or less vulnerable to experi-
encing catastrophic expenditure?” need to become part
of national policy debates. Only then can governments
and policy-makers begin to explore ways of modifying
and adjusting health system performance in order to
protect households from catastrophic expenditure and
impoverishment [18, 28].
Of those who self-reported DM, 87% in China and
71% in India, used medications for DM. A systematic
review and meta-analysis of fifty-six studies (1979–2012)
showed DM treatment rates of 93% in China [51]. In
China’s National Diabetes and Metabolic Disorders
Study, 81% of those who self-reported DM also reported
using insulin or oral hypoglycaemic medicines [52]. A
recently published study by the 10/66 Dementia Re-
search Group found that 93% of people in urban China
self-reported use of pharmacological therapies for DM
[53]. In India the heterogeneity across and within states
makes it difficult to generalise the data more broadly
[54, 55]. Earlier research in India on DM showed that
that 54% of people with DM were on oral hypoglycaemic
agents, 22% on insulin and 20% on combination therapies
[56]. More recently the Indian Council of Medical
Research–India Diabetes (ICMR–INDIAB) Study found
that the use of orally administered hypoglycaemic agents
was 76% among respondents who self-reported DM [57].
Major healthcare reforms introduced by the Chinese
government after 2002 included support and subsidisa-
tion of essential medicines for DM. Between 2001 and
2008 the percentage of OOP payments fell from 60 to
40% [52, 58, 59]. Between 50 and 80% of the cost of care
for DM is met by the Chinese government [50, 60, 61].
Healthcare expenditure as a percentage of Gross
Domestic Product in India is very low (4% in 2008) [13].
The private sector plays a major role in healthcare and
only about 10% of medicines are subsidised by the public
sector [62–64]. India has a rapidly expanding pharma-
ceuticals biotechnology market. In terms of the volume
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Table 2 Multivariable logistic regression of association between socio-demographic and health behavioural characteristics and
diabetes medication use, adults 50+ years, China and India, SAGE Wave 1, 2007–2010
China (n = 773) India (n = 463)
Odds Ratio 95% CI Odds Ratio 95% CI
Lifestyle modification
No 1 Reference 1 Reference
Yes 6.22*** (3.80–10.2) 8.45*** (3.97–18.0)
Sex
Male 1 Reference 1 Reference
Female 1.56* (0.99–2.47) 1.06 (0.45–2.48)
Age groups (years)
50–59 1 Reference 1 Reference
60–69 1.52 (0.84–2.72) 1.08 (0.50–2.30)
70–79 1.53 (0.69–3.36) 1.60 (0.62–4.17)
80+ 3.44** (1.02–11.5) 1.01 (0.45–7.06)
Residence
Urban 1 Reference 1 Reference
Rural 0.85 (0.36–1.98) 1.29 (0.60–2.76)
Marital status
Never married 1 Reference 1 Reference
Married/cohabitating 4.53 (0.38–54.2) 3.49 (0.32–37.7)
Divorced/widowed 6.16 (0.32–119.0) 1.97 (0.16–23.8)
Educational attainment
University or higher 1 Reference 1 Reference
Secondary/High School 0.74 (0.15–3.74) 0.89 (0.26–3.00)
Primary school or less 0.45 (0.10–2.08) 1.60 (0.35–7.43)
Household wealth
1 (Richest) 1 Reference 1 Reference
2 1.37 (0.69–2.80) 0.99 (0.45–2.19)
3 1.55 (0.72–3.36) 0.77 (0.28–2.13)
4 2.13 (0.86–5.26) 0.14** (0.03–0.69)
5 (Poorest) 1.83 (0.62–5.40) 0.47 (0.09–2.30)
BMI
High 1 Reference 1 Reference
Low 0.50*** (0.30–0.83) 1.26 (0.50–3.20)
Nutrition
Adequate 1 Reference 1 Reference
Inadequate 1.18 (0.59–2.35) 0.88 (0.38–2.07)
Physical activity
High 1 Reference 1 Reference
Moderate 1.02 (0.53–1.99) 3.09* (0.94–10.2)
Low 0.44*** (0.25–0.76) 1.88 (0.86–4.11)
Mean Variance Inflation Factor (VIF) China–5.77
Mean Variance Inflation Factor (VIF) India = 4.65
Note: Survey sampling weights applied
95% CI = 95% Confidence Interval
*p-value < 0.10; **p-value < 0.05; ***p-value < 0.01
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of global pharmaceutical production, India ranks fourth,
yet 50 to 65% of the Indian population does not have
access to essential medicines, compared with about 15%
of the population in China [62].
Healthcare expenditure on medications was cata-
strophic for 17% in the China sample and 7% in the
India sample. Although this indicates that 93% of people
in the Indian sample did not experience catastrophic
health expenditure on medications, it must be acknowl-
edged that the majority of India’s population does not
have access to quality affordable healthcare [13]. People
in very poor households may have therefore chosen to
not seek and use healthcare rather than become impo-
verished [65].
India’s health-financing system is more complex than
in other developing countries [13]. The majority of the
country’s healthcare is provided by a largely unregulated
expensive private sector, which favours the rich [8, 66, 67].
India has one of the world’s highest proportions of OOP
payments estimated at 71.1% in 2008–09 [63]. Increased
public sector health financing and involvement is critical
for improving access to healthcare [68].
Our study shows that lifestyle modification in older
adults was predictive of DM medication use in China
and India which is consistent with evidence of health
promotion programs being implemented in China and
India [61, 69]. Rapid economic development in China
and India is fuelling increased urbanisation and major
societal change. The traditional way of life has been sup-
planted by modern urban living which is often associated
with lower levels of physical activity and unhealthy diets.
In addition, aspects of globalisation and industrialization
contribute to overweight and obesity and increase the risk
of chronic diseases such as DM [45, 58, 61, 70–73]. There
is widespread agreement by WHO and other international
health authorities that in addition to the use of essential
medicines, people with DM should also maintain a healthy
lifestyle [74]. Both are concurrent therapies recommended
Table 3 Household characteristics by catastrophic health expenditure, adults 50+ years with diabetes, China and India, SAGE
Wave 1, 2007–2010
China (n = 630) India (n = 439)
Non-catastrophic Catastrophic Non-catastrophic Catastrophic
N (a %) N (a %) N (a %) N (a %)
Overall 524 (83.2) 106 (16.8) 410 (93.4) 29 (6.6)
Diabetes medication
No 68 (14.1) 11 (12.8) 120 (26.8) 9 (24.8)
Yes 456 (85.9) 95 (87.2) 290 (73.2) 20 (75.2)
Lifestyle modification
No 133 (24.5) 26 (29.7) 179 (39.4) 14 (41.3)
Yes 391 (75.5) 80 (70.3) 231 (60.6) 15 (58.7)
Residence
Urban 398 (70.9)*** 63 (50.7) 199 (47.6) 16 (32.6)
Rural 126 (29.1) 43 (49.3) 211 (52.4) 13 (67.4)
Household wealth
1 (Richest) 131 (26.8)*** 12 (8.8) 179 (46.1) 12 (29.5)
2 147 (27.9) 20 (25.4) 114 (24.7) 6 (31.3)
3 118 (22.9) 27 (27.9) 58 (11.5) 5 (11.5)
4 (Poorest 2 quintiles) 128 (22.4) 47 (37.9) 59 (17.8) 6 (27.7)
Household financial status
Very good/Good 102 (18.9) 13 (12.9) 128 (33.0) 15 (52.4)
Moderate 331 (63.0) 66 (63.1) 202 (44.9) 8 (27.8)
Very bad/Bad 91 (18.1) 27 (24.1) 80 (22.2) 6 (19.9)
Educational attainment (household head)
University or higher 45 (8.7)*** 5 (3.3) 81 (21.5) 7 (10.6)
Secondary/High school 246 (44.1) 37 (29.6) 155 (41.4) 7 (35.5)
Primary school or less 233 (47.2) 64 (67.2) 174 (37.1) 15 (53.9)
Pearson χ2 tests undertaken for country comparisons. *p-value < 0.10; **p-value < 0.05; ***p-value < 0.01
asurvey sampling weights used to give percentage estimates. Percentages may not sum due to rounding
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for people with type 2 DM. For example, IDF global
guideline for managing older people with type 2 DM
recommends that health professionals provide advice
and support on lifestyle measures (such as increasing
physical activity, stopping smoking and eating a healthy
diet) in addition to prescribing appropriate medicines
for DM [69].
After adjusting for lifestyle modification and other fac-
tors, female sex was a significant predictor of DM medi-
cation use in older adults in China. The finding is in line
with other epidemiological research on the treatment
and control of DM in China [72, 75]. It is suggested, that
older women are more likely to seek diagnosis and treat-
ment for DM, for example if they experienced gesta-
tional DM during pregnancy, and that men do not pay
attention to their health needs to the same extent [38].
The multivariable regression also showed that high
BMI and high physical activity were predictors of DM
medication use in older men and women in China. An
international study of the association between obesity
and DM demonstrated that a 10 cm increase in waist
circumference and waist-to-height ratio of >0.5 were
associated with significant 1.26 (India) and 1.68 (China)
times higher odds for DM [76]. Research in China shows
that individual’s awareness of having DM increases the
likelihood of their undertaking frequent physical activity
for self-managing their condition [72]. In India DM com-
monly occurs at lower obesity thresholds and at younger
age compared with many other countries [77, 78]. One
theory is that Indian people are genetically predisposed
to the development of coronary artery disease which is
a risk factor for DM [77].
When holding all other variables constant, association
between DM medication use and wealth was positive in
India and negative in China. China’s healthcare reforms
have increased access to DM medicines among the poor
but in India, where there is a dominant private health-
care sector, the rich have better access to DM medicines
Table 4 Multivariable logistic regression of association between DM medication use and household catastrophic health expenditure,
adults aged 50+ with diabetes, China and India, SAGE Wave 1, 2007–2010
China (n = 630) India (n = 439)
Odds Ratio 95% CI Odds Ratio 95% CI
Diabetes medication
No 1 Reference 1 Reference
Yes 1.32 (0.50–3.51) 1.16 (0.29–4.62)
Lifestyle modification
No 1 Reference 1 Reference
Yes 0.83 (0.48–1.45) 1.01 (0.32–3.14)
Residence
Urban 1 Reference 1 Reference
Rural 1.62** (1.01–2.61) 1.60 (0.28–9.24)
Wealth quintile
1 (Richest) 1 Reference 1 Reference
2 2.38** (1.21–4.66) 3.20 (0.42–24.19)
3 2.88*** (1.37–6.07) 3.01 (0.62–14.58)
4 (Poorest 2 quintiles) 3.49** (1.37–8.87) 5.95* (0.79–44.89)
Household financial status
Very good/Good 1 Reference 1 Reference
Moderate 0.98 (0.45–2.14) 0.15*** (0.04–0.55)
Very bad/Bad 0.95 (0.40–2.26) 0.14** (0.03–0.82)
Educational attainment (household head)
University or higher 1 Reference 1 Reference
Secondary/High school 1.08 (0.36–3.26) 1.45 (0.18–11.45)
Primary school or less 1.68 (0.60–4.70) 2.64 (0.41–16.98)
Mean Variance Inflation Factor (VIF) China = 2.09
Mean Variance Inflation Factor (VIF) India = 1.56
Note: Survey sampling weights applied
95% CI = 95% Confidence Interval
*p-value < 0.10; **p-value < 0.05; ***p-value < 0.01
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[8, 66–68]. These findings are consistent with global evi-
dence that in the economically less prosperous developing
countries, DM is more prevalent among the rich, but as
the pace of economic development increases the asso-
ciation is reversed. Since the 1990s China’s economy
has grown faster than that of any other country and
this has led to major improvements in income and living
standards [7, 12].
China is ahead of India in terms of the implementation
of national plans which cover the universal monitoring
and surveillance of DM resulting in increased numbers
of people being diagnosed and treated [51, 52, 61]. The
2015 the IDF global ranking of absolute numbers of
adults (20–79 years) with DM, placed China first (109.6
million) and India second (69.2 million) [16]. However
expenditure patterns differ. In 2015 China spent 90 billion
International Dollars (ID) on DM-related expenditure,
ranking second only to the United States (ID 320 billion).
In the same year India spent ID23 billion [16] on DM-
related expenditure.
Diabetes medication use was not a significant pre-
dictor of catastrophic healthcare expenditure in the
presence of lifestyle modification, residence, household
wealth, household financial status and the household
heads’ educational attainment, in either China or India.
In the multivariable analysis in China, rural residents
were significantly more likely to experience catastrophic
healthcare expenditure compared with urban residents.
Yet these results must be interpreted within a broader
health policy context. China has made notable progress
in expanding government-funded health insurance
thereby improving access to medicines and other health-
care across the population. In urban areas health insur-
ance has been extended to the non-employed (e.g.,
students, the elderly, unemployed) and rural coverage
increased from 20% in 2003 to over 85% in 2007 [50].
However there is still a way to go and many people are
experiencing catastrophic expenditure due to low
levels of paid benefits or subsidies. Our findings show
that the proportion of people experiencing cata-
strophic healthcare expenditure was higher among
those in rural areas, with lower education and less
wealth.
In the Indian sample large sections of the population
still do not have affordable access to healthcare. The
country difference can be attributed to interaction be-
tween poverty and out-of-pocket (OOP) payments
within the context of two very different healthcare systems
[10, 50, 79]. Although the probability of catastrophic
expenditure is high where poverty levels are high, poverty
can result in the exclusion of some sections of the popula-
tion from healthcare. In this way poverty can provide a
somewhat perverse “protection” from catastrophic ex-
penditure [28, 30].
In China older adults with reported DM who were
less wealthy were significantly more likely to live in
households with catastrophic healthcare expenditure on
medications after adjusting for the effects of DM medi-
cation use, lifestyle modification, residence, household
financial status and household head’s educational at-
tainment. This evidence is consistent with research by
Li et al. [30] which showed that a number of factors in
combination increase the risk of catastrophic healthcare
expenditure. They included being older, having chronic
illness and living in rural or socioeconomically deprived
areas. Additionally Li et al. [30] suggested that although
healthcare utilisation in China has increased due to the
expanded breadth in healthcare coverage, low benefit
levels are contributing to a higher burdens from OOP
payments.
In India older adults with reported DM, with very
good or good household financial status, were signifi-
cantly more likely to live in households with catastrophic
healthcare expenditure, compared with their counter-
parts with moderate, very bad or bad household financial
status. This association remained after adjusting for the
effects of DM medication use, lifestyle modification, resi-
dence, household wealth, and the household head’s edu-
cational attainment. However, this does not mean that
lower household financial status is protective of cata-
strophic healthcare expenditure. In this analysis the
determinants of catastrophic healthcare expenditure in
India need to be understood in the context of equity of
access to medication use. In India DM medication use in
older adults in the richest wealth quintile was 48.3%
compared with 3.9 and 7.2% in the poorest two quintiles.
There was also a significant association (p < 0.05)
between DM medication use and household financial
status with 85% of older adults in households with very
good or good financial status reporting medication use,
compared with 74 and 56% of older adults in households
with moderate or very bad household financial status.
(Results not shown).
Our findings reflect recent policies and action under-
taken in response to the growing burden of DM within
the global UHC agenda [61]. Both India and China have
committed public funds into healthcare programs for
NCDs [29]. China has launched a number of health
reforms aimed at improving social health insurance
schemes and strengthening primary healthcare [52, 60, 80].
India’s publically-funded health schemes have focused
exclusively on inpatient secondary and tertiary care to the
neglect of primary healthcare [64] and progress has been
impeded by the country’s vast geographic and ethnic
diversity [61]. The Indian healthcare system requires a
major shift from the traditional paradigm of catering
for infectious diseases and maternal and child health,
towards primary and secondary prevention, diagnosis,
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treatment and ensuring the availability and affordability
of medications for DM and other NCDs [77, 81].
Strengths and limitations
We acknowledge the possibility of selection bias because
study samples were conditioned on self-reported DM.
The use of self-reported measures of chronic disease
may substantially underestimate disease prevalence in
LMICs, especially within population sub-groups with
lower socioeconomic status. An analysis of data from the
six SAGE countries found that socioeconomic inequalities
in NCD prevalence are more likely to be positive when
using self-report compared with symptom-based or
criterion-based diagnostic criteria, with greater bias occur-
ring in low-income countries [82].
It is difficult to make accurate comparisons between
DM prevalence across studies. Estimates are derived and
modelled using a range of methods, definitions, clinical
criteria and sampling techniques across geography,
demography and time. The purpose of the analysis (e.g.,
policy or research) is also relevant to the way in which
estimates are derived. Nevertheless the quality of WHO-
SAGE data is high and these findings are broadly con-
sistent with other major population based studies of DM
in China and India.
While every attempt was made to standardise the
SAGE survey instruments it is possible that different
social and cultural perceptions about DM many have
introduced bias. However it is not possible for us to say
to what extent this might have occurred.
Other studies have found that people with DM in
China and India delay seeking care for financial reasons
until after they have developed more serious medical
complications [29, 83]. However it is also not possible to
ascertain the extent to which this may have occurred here.
The data for this study were cross sectional and there-
fore causation cannot be assumed in any direction. The
analyses cover SAGE Wave 1 data which were collected
between 2007 and 2010 in China and India. Future
waves of SAGE will enable more wide-ranging analyses
of these issues concordant with UHC policies and NCD
prevention programmes.
The WHO Study on AGEing and Adult Health
(SAGE) provides valid, reliable, comparable national data
on important public health outcomes in adults aged 50
and above in China, Ghana, India, Mexico, Russian
Federation and South Africa [39]. WHO-SAGE surveys
were conducted in the six countries in a highly stan-
dardized manner. The questionnaires are first translated
into the local language, back translated and validated.
WHO-SAGE implemented the quality assurance proce-
dures for household surveys recommended by the
United Nations.
WHO-SAGE data have been widely analysed and re-
ported in hundreds of peer-reviewed publications. See
http://www.who.int/healthinfo/sage/articles_all/en/. num-
ber of such have added to policy evidence by focusing spe-
cifically on comparisons between China and India [5, 9,
10, 79]. This study adds to that important body of
work.
In the past it has been difficult to make valid cross-
country comparisons of catastrophic healthcare expen-
ditures because studies have used a range of variable
definitions, expenditure thresholds, study designs, and
sampling methods [37]. This is the first study of its
kind to use a standardised approach allowing a com-
parative analysis of data from China and India.
It is more common in studies of this type to include
the condition of interest, for example DM, as the inde-
pendent variable which can mean that undiagnosed cases
are erroneously defined as non-cases [29]. Although we
have limited our sample size by only including people with
reported DM, this allowed an explicit analysis for targeted
policy interventions.
Conclusions
The country comparison reflects major public policy dif-
ferences underpinned by divergent political and ideo-
logical frameworks. China’s expansion of healthcare
coverage has increased service access and utilisation but
low benefits paid to households have impacted on
OOPs. In India healthcare coverage is limited and the
government faces ongoing challenges in responding to
the health needs of disadvantaged groups in the popula-
tion. Findings from this study also help reiterate the im-
portance of behavioural factors as essential components
of DM management. Health policies and guidelines rele-
vant to DM must therefore incorporate lifestyle modifi-
cation strategies for effective prevention and control of
DM and associated complications. Ensuring equitable
and affordable access to medications for DM among
older adult populations is fundamental for healthier
ageing cohorts and is consistent with the global agenda
for UHC.
Abbreviations
BMI: Body mass index; CI: Confidence interval; DM: Diabetes mellitus;
IDF: International Diabetes Federation; KGs: Kilograms; LMICs: Low- and
middle-income countries; Ms: Metres; NCDs: Non-communicable diseases;
OOP: Out-of-pocket; OR: Odds ratio; PSUs: Primary sampling units;
SAGE: Study on global AGEing and adult health; UHC: Universal healthcare
coverage; VIF: Variance inflation factor; WHO: World Health Organization
Acknowledgements
We are grateful to the respondents of SAGE Wave 1 in China, India, Ghana
and South Africa and to the WHO for making the WHO-SAGE dataset publicly
available. Support for the SAGE-Wave 1 was provided by the United States
National Institute on Aging (NIA) Division of Behavioral and Social Research
(BSR) through Interagency Agreements (YA1323–08-CN-0020; Y1-AG-1005–01).
We are very grateful to Anni-Maria Pulkki-Brännström who provided health
economics input and guidance during the conception of the study. In
Gwatidzo and Stewart Williams BMC Geriatrics  (2017) 17:14 Page 12 of 15
addition we are most appreciative of the excellent feedback given by the
reviewers and the editor.
Funding
At the time of writing Shingai Gwatidzo was a Swedish Institute (SI) Scholarship
Holder for MPH program at Umeå University. Jennifer Stewart-Williams was
supported by the FORTE grant for the Umeå Centre for Global Health Research
(No. 2006–1512). The funders had no role in study design, data collection,
analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
The anonymised datasets are in the public domain: http://apps.who.int/
healthinfo/systems/surveydata/index.php/catalog/central
SAGE is committed to the public release of study instruments, protocols and
meta- and micro-data: access is provided upon completion of the Users
Agreement available through WHO’s SAGE website: www.who.int/healthinfo/
systems/sage and the WHO archive using the National Data Archive application
(http://apps.who.int/healthinfo/systems/surveydata). The questionnaires and
other materials can be found at: http://www.who.int/healthinfo/sage/cohorts/
en/index2.html SAGE is committed to the public release of study instruments,
protocols and meta- and micro-data: access is provided upon completion of
the Users Agreement available through WHO’s SAGE website (www.who.int/
healthinfo/systems/sage).
Authors’ contributions
SGD made a substantial contribution to the conception of the study,
analyzed the data, wrote the first draft and reviewed the literature. JSW
developed the first and last drafts, extended the literature review, checked
the analyses, and provided critical inputs and advice at all stages of the
manuscript. Both authors read and approved the final draft.
Authors’ information
SGD is a pharmacist and public health professional. JSW is an epidemiologist
in global public health.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
The data were provided after completion of User’s agreement available through
the WHO SAGE website. (Information provided below). The manuscript does not
contain individual persons’ data therefore statement of consent is not
applicable.
Ethics approval and consent to participate
The WHO-SAGE study was approved by the Ethics Review Committee, World
Health Organization, Geneva, Switzerland and the individual ethics committees
in each of the SAGE countries. Informed consent was obtained from all
respondents before the interviews were initiated.
Author details
1Umeå International School of Public Health, Unit of Epidemiology and
Global Health, Department of Public Health and Clinical Medicine, Faculty of
Medicine, Umeå University, SE-90185 Umeå, Sweden. 2Unit of Epidemiology
and Global Health, Department of Public Health and Clinical Medicine,
Faculty of Medicine, Umeå University, SE-90185 Umeå, Sweden. 3Research
Centre for Gender, Health and Ageing, Faculty of Health, University of
Newcastle, New Lambton Heights, Newcastle NSW 2305, New South Wales,
Australia.
Received: 14 June 2016 Accepted: 27 December 2016
References
1. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR,
Fathima S, Feigl AB, Gaziano T, Mowafi M, Pandya A, Prettner K,
Rosenberg L, Seligman B, Stein AZ, Weinstein C. The Global Economic
Burden of Noncommunicable Diseases. Geneva: World Economic Forum;
2011.
2. World Health Organization. Global status report on noncommunicable
diseases 2014. Genève: WHO; 2014.
3. United Nations. Resolution 66/2. Political declaration of the high-level
meeting of the general assembly on the prevention and control of
noncommunicable diseases. In sixty-sixth session of the United Nations
General Assembly. New York: United Nations; 2011.
4. He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population
Reports, P95/16-1, An Aging World: 2015. Washington, DC: U.S. Government
Publishing Office; 2016.
5. Chatterji S, Kowal P, Mathurs C, Naidoo N, Verdes E, Smith JP, et al. The health
of aging populations in China and India. Health Aff. 2008;27(4):1052–63.
6. Kowal P. China and India’s challenges: the other end of the spectrum.
Lancet. 2008;372:1459.
7. Bloom DE, Canning D, Hu L, Liu Y, Mahal A, Yip W. The contribution of
population health and demographic change to economic growth in China
and India. J Comp Econ. 2010;38(1):17–33.
8. Bloom DE, Cafiero ET, McGovern ME, Prettner K, Stanciole A, Weiss J, et al.
The economic impact of non-communicable disease in China and India:
estimates, projections, and comparisons. Cambridge Massachusetts: National
Bureau of Economic Research; 2013. Report No.
9. Kowal P, Williams S, Jiang Y, Wu F, Arokiasamy P. S C. Aging, Health, and
Chronic Conditions in China and India: results from the multinational study
on global AGEing and adult health (SAGE). In: Smith JS, Majmundar M,
editors. National Research Council (US) panel on policy research and data
needs to meet the challenge of aging in asia. 17. Washington (DC): National
Academies Press (US); 2012. p. 12.
10. Kumar K, Shukla A, Singh A, Rama F, Kowal P. Association between wealth
and health among older adults in rural China and India. J Econ Ageing.
2016;7:43–52.
11. United Nations. World Population Prospects. The 2015 revision. Key findings
and advance tables. New York: The United Nations Department of
Economics and Social Affairs Population Division; 2015.
12. Dollar D. Poverty, inequality, and social disparities during China’s economic
reform. Policy, Research working paper; no. WPS 4253. Washington, DC:
World Bank; 2007. http://documents.worldbank.org/curated/en/
182041468241155669/Poverty-inequality-and-social-disparities-during-
Chinas-economic-reform. Accessed 16 May 2016.
13. Chatterjee P. India tries to break cycle of health-care debt. Bull World Health
Organ. 2010;88:486–7.
14. Bhutani J, Bhutani S. Worldwide buren of diabetes. Indian J Endocrinol
Metab. 2014;18(6):868–70.
15. Egan AM, Dinneen SF. What is diabetes? Medicine. 2014;42(12):679–81.
16. International Diabetes Federation. IDF diabetes atlas. Seventhth ed. 2015.
Contract No.: ISBN: 978-2-930229-81-2.
17. Beard JR, Biggs S, Bloom DE, Fried LP, Hogan P, Kalache A, Olshansky SJ,
eds., Global population ageing: Peril or promise. Genève: World Economic
Forum; 2011.
18. Bloom DE, Mahal A, Rosenberg L, et al. Design and operation of health
systems in developing countries. Chapter 13. In: John R, Beard JR, Biggs S,
Bloom DE, Fried LP, Hogan P, Kalache A, editors. Global population ageing:
peril or promise? Genève: World Economic Forum; 2011. p. 148.
19. Maher D, Ford N, Unwin N. Priorities for developing countries in the global
response to non-communicable diseases. Globalization Health. 2012;8:14.
doi:10.1186/1744-8603-8-14.
20. United Nations General Assembly. Transforming our world: the 2030 agenda for
sustainable development. New York: United Nations General Assembly; 2015.
21. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.
22. Bristol N. Global health action toward universal health coverage.
Washington DC: Center for Strategic and International Studies; 2014.
23. World Health Organization, World Bank. Monitoring progress towards
universal health coverage at country and global levels. Geneva: WHO and
World Bank Group; 2014. Contract No.: WHO/HIS/HIA/14.1.
24. Peltzer K, Stewart Williams J, Kowal P, Negin J, Snodgrass J, Yawson A,
et al. Universal health coverage in emerging economies: findings on
health care utilization by older adults in China, Ghana, India, Mexico,
the Russian Federation, and South Africa. Glob Health Action.
2014;7:25314.
25. World Health Organization. The World Health Report - health systems
financing: the path to universal coverage. Geneva: WHO; 2010. Contract No.:
WHO Report ISBN 978 92 4 156402 1.
26. Van Doorslaer E, O'Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR,
Garg CC, et al. Catastrophic payments for health care in Asia. Health Econ.
2007;16(11):1159–84.
Gwatidzo and Stewart Williams BMC Geriatrics  (2017) 17:14 Page 13 of 15
27. World Bank. The World Bank Open Data. 2016. Available from: http://data.
worldbank.org/indicator/SH.XPD.OOPC.ZS. Accessed 16 May 2016.
28. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. In: Murray CJL,
Evans DB, editors. Understanding household catastrophic health expenditures:
a multi-country analysis. Geneva: World Health Organisation; 2003.
29. Smith-Spangler CM, Bhattacharya J, Goldhaber-Fiebert JD. Diabetes, its
treatment, and catastrophic medical spending in 35 developing countries.
Diabetes Care. 2012;35(2):319–26.
30. Li Y, Wu Q, Xu L, Legge D, Hao Y, Gao L, et al. Factors affecting catastrophic
health expenditure and impoverishment from medical expenses in China:
policy implications of universal health insurance. 2012.
31. Brinda EM, Rajkumar AP, Enemark U, Prince M, Jacob KS. Nature and
determinants of out-of-pocket health expenditure among older people in
a rural Indian community. Int Psychogeriatr. 2012;24(10):1664–73.
32. Brinda EM, Kowal P, Attermann J, Enemark U. Health service use, out-of-
pocket payments and catastrophic health expenditure among older people
in India: The WHO Study on global AGEing and adult health (SAGE). J
Epidemiol Community Health 2015;69:489-94. doi:10.1136/jech-2014-204960.
33. Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-
communicable diseases in low- and middle-income countries: a literature
review. Health Res Policy Syst. 2013;11:31.
34. Jaspers L, Colpani V, Chaker L, van der Lee SJ, Muka T, Imo D, et al. The
global impact of non-communicable diseases on households and
impoverishment: a systematic review. Eur J Epidemiol. 2015;30(3):163–88.
35. Yang W, Zhao W, Xiao J, Li R, Zhang P, Kissimova-Skarbek K, et al. Medical
Care and Payment for Diabetes in China: Enormous Threat and Great
Opportunity. PLoS ONE. 2012;7(9):e39513. doi:10.1371/journal.pone.0039513.
36. Saksena P, Ke Xu K, Evans DB. Impact of out of pocket payments for
tresatment of non communicable diseases in developing countries: a review
of the literature. Geneva: WHO; 2011. Contract No.: HSS/HSF/DP.E.11.2.
37. Goryakin Y, Suhrcke M. The prevalence and determinants of catastrophic
health expenditures attributable to non-communicable diseases in low- and
middle-income countries: a review-based commentary on the
methodological challenges involved. Int J Equity Health. 2014;13(1):107.
38. International Diabetes Federation. A call to action on diabetes. 2010. Report No.
39. Kowal P, Chatterji S, Naidoo N, Biritwum R, Fan W, Lopez Ridaura R, et al.
Data resource profile: the World Health Organization Study on global
AGEing and adult health (SAGE). Int J Epidemiol. 2012;41:1639–49. England.
40. Naidoo N. Working Paper Number 5. In: WHO, editor. WHO’s Study on
global AGEing and adult health (SAGE) Waves 0 and 1 sampling
information for China, Ghana, India, Mexico, Russia and South Africa.
Geneva: World Health Organization SAGE; 2012. p. 9
41. World Health Organization. Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies.
Lancet. 2004;363:157–63.
42. World Health Organization. Diet, nutrition and the prevention of chronic
diseases. Genève: 2002 28 January – 1 February 2002. Report No.: Contract
No.: WHO Technical Report Series 916.
43. He W, Muenchrath M, Kowal P. Shades of Gray: a cross-country study of
health and well-being of the older populations in SAGE countries, 2007–2010.
Washington DC: US Department of Health and Human Services; 2012. Contract
No.: P95/12-01.
44. World Health Organization. Global Physical Activity Questionnaire (GPAQ).
Analysis Guide. Surveillance and Population‐Based Prevention. Genève:
WHO; 2006.
45. World Health Organization. Global strategy on diet. physical activity and
health. Geneva: WHO; 2004. Report No.
46. Ferguson B, Murray C, Tandon AEG. In: Murray C, Evans D, editors.
Estimating permanent income using asset and indicator variables. Geneva:
World Health Organisation; 2003.
47. Howe LD, Galobardes B, Matijasevich A, Gordon D, Johnston D, Onwujekwe
O, et al. Measuring socio-economic position for epidemiological studies in
low- and middle-income countries: a methods of measurement in
epidemiology paper. Int J Epidemiol. 2012;41(3):871–86.
48. Shaikh BT, Hatcher J. Health seeking behaviour and health service utilization
in Pakistan: challenging the policy makers. J Public Health. 2004;27(1):49–5.
49. Babitsch B, Gohl D, von Lengerke T. Re-revisiting Andersen’s behavioral
model of health services Use: a systematic review of studies from 1998–2011.
GMS Psycho-Social-Medicine. 2012;9:15.
50. Strauss J, Hong H, Lei X, Li L, Park A, Yang L, et al. Healthcare and insurance
among the elderly in China: evidence from the CHARLS pilot. In: Smith JP,
Majmundar M, editors. National Research Council (US) panel on policy
research and data needs to meet the challenge of aging in asia.
Washington (DC): National Academies Press (US); 2012. p. 29.
51. Li MZ, Su L, Liang BY, Tan JJ, Chen Q, Long JX, et al. Trends in prevalence,
awareness, treatment, and control of diabetes mellitus in mainland China
from 1979 to 2012. Int J Endocrinol. 2013;2013:753150.
52. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes
among men and women in China. N Engl J Med. 362. United States: 2010
Massachusetts Medical Society; 2010. p. 1090–101.
53. Salas A, Acosta D, Ferri CP, Guerra M, Huang Y, Jacob K, et al. The
prevalence, correlates, detection and control of diabetes among older
people in low and middle income countries. A 10/66 Dementia Research
Group Population-Based Survey. PlosOne. 2016;11(2):17.
54. Mohan V, Mathur P, Deepa R, Deepa M, Shukla DK, Menon GR, et al. Urban
rural differences in prevalence of self-reported diabetes in India–the WHO-
ICMR Indian NCD risk factor surveillance. Diabetes Res Clin Pract. 80.
Ireland2008. p. 159–68.
55. Anjana RM, Ali MK, Pradeepa R, Deepa M, Datta M, Unnikrishnan R, et al.
The need for obtaining accurate nationwide estimates of diabetes
prevalence in India - rationale for a national study on diabetes. Indian J
Med Res. 2011;133(4):369–80.
56. Raheja BS, Kapur A, Bhoraskar A, Sathe SR, Jorgensen LN, Moorthi SR, et al.
DiabCare Asia–India Study: diabetes care in India–current status. J Assoc
Physicians India. 2001;49:717–22.
57. Unnikrishnan R, Mohan Anjana R, Deepa M, Pradeepa R, Joshi SR, Bhansali
A, et al. Glycemic control among individuals with self-reported diabetes in
India—the ICMR–INDIAB study. Diabetes Technol Ther. 2014;16(9):596–603.
58. Pan C. Diabetes care in China: meeting the challenge. China: Beijing; 2005.
59. Liu S, Wang W, Zhang J, He Y, Yao C, Zeng Z, et al. Prevalence of
diabetes and impaired fasting glucose in Chinese adults, China National
Nutrition and Health Survey, 2002. Prev Chronic Dis. 2011;8(1). http://
www.cdc.gov/pcd/issues/2011/jan/10_0008.htm. Accessed 26 Oct 2016.
60. Meng Q, Xu L. Monitoring and evaluating progress towards universal health
coverage in China. PLoS Med. 2014;11(9):3.
61. International Diabetes Federation. Global diabetes scorecard. Brussels:
International Diabetes Federation; 2014.
62. World Health Organization. World medicines situation. Geneva: WHO; 2004.
63. Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India.
Lancet. 2011;377(9764):505–15.
64. Sengupta A. Universal health care in India making it public, making it a
reality. Canadian Giovernment International Development Research Centre
(IDRC). 2013. Report No.
65. Engelgau MM, Karan A, Mahal A. The economic impact of non-
communicable diseases on households in India. Glob Health. 2012;8(9):10.
66. Evans JM, Kiran PR, Bhattacharyya OK. Activating the knowledge-to-action
cycle for geriatric care in India. Health Res Policy Syst. 2011;9(42):10.
67. Dey S, Nambiar D, Lakshmi JK, Sheikh K, Redd S. Health of the elderly in
India: challenges of access and affordability. In: Smith J, Majmundar M,
editors. National Research Council (US) panel on policy research and data
needs to meet the challenge of aging in asia. Washington (DC): National
Academies Press (US); 2012. p. 30.
68. Duggal R. Poverty and health: Criticality of public financing. Indian J Med
Res. 2007:126:309–17.
69. International Diabetes Federation. Managing older people with Type 2
diabetes: global guideline. Brussels: International Diabetes Federation; 2013.
70. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The
Indian diabetes prevention programme shows that lifestyle modification
and metformin prevent type 2 diabetes in asian Indian subjects with
impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.
71. Whiting D, Unwin D, Roglic G. Diabetes: equity and social determinants.
In: Blas E, Sivasankara Kurup A, editors. Equity, social determinants and
public health programmes. Geneva (Switzerland): World Health
Organization; 2010. p. 77–94.
72. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, et al. Awareness, treatment,
control of diabetes mellitus and the risk factors: survey results from
northeast China. PLoS ONE. 2014;9(7):e103594.
73. Yesudian CAK, Grepstad M, Visintin E, Ferrario A. The economic burden of
diabetes in India: a review of the literature. Glob Health. 2014;10:80.
74. World Health Organization. Prevention and control of noncommunicable
diseases: guidelines for primary healthcare in low resource settings. Geneva:
WHO; 2012.
Gwatidzo and Stewart Williams BMC Geriatrics  (2017) 17:14 Page 14 of 15
75. Xu X, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of
diabetes in Chinese adults. JAMA. 2013;310(9):948–59.
76. Tyrovolas S, Koyanagi A, Garin N, Olaya B, Ayuso-Mateos JL, Miret M, et al.
Diabetes mellitus and its association with central obesity and disability
among older adults: a global perspective. Exp Gerontol. 2015;64:70–7.
77. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India.
Australasian Med J. 2014;7(1):45–8.
78. Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes
control: key issues. Australasian Med J. 2013;6(10):524–31.
79. Kumar K, Singh A, Kumar S, Ram F, Singh A, Ram U, et al. Socio-economic
differentials in impoverishment effects of out-of-pocket health expenditure
in China and India: evidence from WHO SAGE. PlosOne. 2015;10(8):19.
80. Lall D, Prabhakaran D. Organization of primary health care for diabetes and
hypertension in high, low and middle income countries. Expert Rev
Cardiovasc Ther. 2014;12(8):987–95.
81. Venkataraman K, Kannan AT, Mohan V. Challenges in diabetes management
with particular reference to India. Int J Diab Develop Ctries. 2009;29(3):103–9.
82. Vellakkal S, Millett C, Basu S, Khan Z, Aitsi-Selmi A, Stuckler D, et al. Are
estimates of socioeconomic inequalities in chronic disease artefactually
narrowed by self-reported measures of prevalence in low-income and
middle-income countries? Findings from the WHO-SAGE survey. J Epidemiol
Community Health. 2015;69(3):218–25.
83. Goldhaber-Fiebert JD, Ratanawijitrasin S, Vidyasagar S, Wang XY, Aljunid S,
Shah N, et al. Inpatient treatment of diabetic patients in Asia: evidence from
India, China. Thailand and Malaysia Diabet Med. 2010;27(1):101–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gwatidzo and Stewart Williams BMC Geriatrics  (2017) 17:14 Page 15 of 15
